Phase ll study evaluating the toxicity and efficacy of a modified German Paediatric Hodgkin's Lymphoma protocol (HD95) in young adults (aged 18-30 years) with Hodgkin's Lymphoma
Read time: 1 mins
Last updated:3rd Sep 2007
Main objective of this study is to determine whether young adults (18-30 years) can receive modified HD95 therapy without experiencing excessive neurotoxicity due to the intensive use of Vinca alkaloids in this regimen.
|Study start date||2007-09-03|